Jennifer I Lim, Ogugua N Okonkwo, Sally S Ong, Carl D Regillo, Adrienne W Scott, Charles C Wykoff, Jessica Cao, Alicia Chen, Bernadette A Miao, Bita Momenaei, Jianyou Liu
{"title":"抗血管内皮生长因子治疗3期和4期增殖性镰状细胞视网膜病变改善解剖和视力结果","authors":"Jennifer I Lim, Ogugua N Okonkwo, Sally S Ong, Carl D Regillo, Adrienne W Scott, Charles C Wykoff, Jessica Cao, Alicia Chen, Bernadette A Miao, Bita Momenaei, Jianyou Liu","doi":"10.1097/IAE.0000000000004658","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the potential utility of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR).</p><p><strong>Methods: </strong>Retrospective review of anatomic and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.</p><p><strong>Results: </strong>There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received 2 both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean= 21 months). Within 1 month after anti-VEGF treatment, VA improved > 2 lines in 17/45 eyes, remained stable in 27/45 eyes and worsened in 1/45 eyes. Median visual acuity remained 20/20 for stage 3 and improved from 20/200 to 20/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement post-treatment than stage 3 PSR eyes (P=0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42/45 (93%) of eyes without the need for pars plana vitrectomy.</p><p><strong>Conclusion: </strong>Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12529713/pdf/","citationCount":"0","resultStr":"{\"title\":\"Anti-Vascular Endothelial Growth Factor Therapy for Stages 3 and 4 Proliferative Sickle Cell Retinopathy Results in Improved Anatomic and Visual Outcomes.\",\"authors\":\"Jennifer I Lim, Ogugua N Okonkwo, Sally S Ong, Carl D Regillo, Adrienne W Scott, Charles C Wykoff, Jessica Cao, Alicia Chen, Bernadette A Miao, Bita Momenaei, Jianyou Liu\",\"doi\":\"10.1097/IAE.0000000000004658\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To investigate the potential utility of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR).</p><p><strong>Methods: </strong>Retrospective review of anatomic and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.</p><p><strong>Results: </strong>There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received 2 both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean= 21 months). Within 1 month after anti-VEGF treatment, VA improved > 2 lines in 17/45 eyes, remained stable in 27/45 eyes and worsened in 1/45 eyes. Median visual acuity remained 20/20 for stage 3 and improved from 20/200 to 20/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement post-treatment than stage 3 PSR eyes (P=0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42/45 (93%) of eyes without the need for pars plana vitrectomy.</p><p><strong>Conclusion: </strong>Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.</p>\",\"PeriodicalId\":54486,\"journal\":{\"name\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12529713/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IAE.0000000000004658\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004658","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Anti-Vascular Endothelial Growth Factor Therapy for Stages 3 and 4 Proliferative Sickle Cell Retinopathy Results in Improved Anatomic and Visual Outcomes.
Purpose: To investigate the potential utility of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR).
Methods: Retrospective review of anatomic and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.
Results: There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received 2 both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean= 21 months). Within 1 month after anti-VEGF treatment, VA improved > 2 lines in 17/45 eyes, remained stable in 27/45 eyes and worsened in 1/45 eyes. Median visual acuity remained 20/20 for stage 3 and improved from 20/200 to 20/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement post-treatment than stage 3 PSR eyes (P=0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42/45 (93%) of eyes without the need for pars plana vitrectomy.
Conclusion: Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.
期刊介绍：
RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice.
In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color.
Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
